Benzinga | Jun 23, 2021 06:05AM EDT

GlaxoSmithKline Sees Sales Growth More Than 5% And Adjusted Operating Profit Growth More Than 10% CAGR 2021-26; Cash Generated From Operations Expected To Exceed 10B By 2026

-Reuters